Work

Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease

Year: 2018

Type: article

Abstract: Nephrology Dialysis Transplantation, gfx350, https://doi.org/10.1093/ndt/gfx350 In the above article, the n numbers for the least squares mean values (LSM) reported below figure 2A were incorrect. The numbers for Week 102 were repeated under the graph rather than displaying the true LSM values, which were 62 for placebo, 55 for dapagliflozin 5 mg and 85 for dapagliflozin 10 mg. The authors apologise for the error which has been corrected.

Source: Nephrology Dialysis Transplantation

DOI: 10.1093/ndt/gfy135

Authors: Claire C J Dekkers, David C Wheeler, C David Sjöström, Bergur V Stefansson, Valerie Cain, Hiddo J L Heerspink

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,926

OpenAlex ID: W4252551836